Perhaps you could do some research, starting with the Dimerix website, and especially information on their drug discovery platform. This platform is designed to identify conditions where a combination of two drugs are indicated to treat the underlying condition (hint: the "Di" in Dimerix means "2"). In the case of DMX-200, the two drugs are Propagermanium in conjuction with Irbesartan. The former has been around for decades as a non-prescription "health tonic", the latter is an off-patent angiotensin receptor blocker (ARB) used to treat high blood pressure (which can be damaging to kidneys).
https://announcements.asx.com.au/asxpdf/20170913/pdf/43m8sjgy5ylgdm.pdf
Ann: Investor Presentation, page-131
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.015(3.41%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 46.0¢ | 43.5¢ | $698.9K | 1.543M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 136150 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 27000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |